Pharmaceuticals company Lupin announced Q1FY27 results Consolidated Financial Highlights: Total Revenue from operations in Q1FY27 reached Rs 82,768.9 million, reflecting a YoY growth of 32.04% compared to Rs 62,683.4 million in Q1/FY26 and a QoQ increase of 10.73% from Rs 74,746.6 million in Q4FY26. Total income for the group stood at Rs 84,072.1 million in Q1FY27, up 32.45% YoY from Rs 63,473.8 million in Q1FY26 and 10.40% higher QoQ than Rs 76,153.7 million in Q4FY26. Profit before tax and exceptional items in Q1FY27 was Rs 20,173.6 million, an increase of 42.51% YoY over Rs 14,155.4 million in Q1FY26 and a 4.63% growth QoQ compared to Rs 19,280.0 million in Q4FY26. Net Profit after tax for Q1FY27 was Rs 14,169.8 million, marking a YoY growth of 16.01% from Rs 12,214.6 million in Q1FY26, while declining 3.52% QoQ from Rs 14,686.7 million in Q4FY26. Standalone Financial Highlights: Total Revenue from operations in Q1FY27 was Rs 71,719.0 million, representing a YoY increase of 25.63% from Rs 57,085.9 million in Q1FY26 and a QoQ increase of 37.01% from Rs 52,346.0 million in Q4FY26. Total income in Q1FY27 stood at Rs 72,743.8 million, growing 26.23% YoY from Rs 57,627.3 million in Q1FY26 and 36.65% QoQ from Rs 53,234.3 million in Q4FY26. Profit before tax for Q1FY27 was Rs 36,100.6 million, an increase of 39.48% YoY from Rs 25,881.5 million in Q1FY26 and a 38.72% QoQ increase from Rs 26,023.5 million in Q4FY26. Net Profit after tax reached Rs 27,146.0 million in Q1FY27, reflecting a YoY growth of 27.56% from Rs 21,280.7 million in Q1FY26 and a 25.46% QoQ growth from Rs 21,636.9 million in Q4FY26. The standalone profit for Q1FY27 includes a reversal of provision amounting to Rs 4,493.9 million (USD 50.0 million) related to Generic Pharmaceuticals Antitrust Litigation, which was recorded by a subsidiary. Business Highlights: Segment Performance: Pharmaceuticals: Revenue from operations in Q1FY27 was Rs 82,343.5 million compared to Rs 62,364.1 million in Q1FY26. Segment results (profit) for the quarter stood at Rs 20,605.6 million. Others: Revenue from operations was Rs 430.3 million in Q1FY27 compared to Rs 322.8 million in Q1FY26. Segment results for the quarter showed a loss of Rs 432.0 million. Acquisitions: On April 01, 2026, the company, through its subsidiary, concluded the acquisition of VISUfarma B.V., Netherlands, for a total consideration of Rs 20,902.7 million (Euro 192.8 million). Arbitration Award: During Q1FY27, the Group received an arbitration award and consequently accounted for an income of Rs 603.2 million (USD 6.9 million). Litigation Settlement: In April 2026, a wholly owned subsidiary settled an ongoing litigation dispute for an amount of Rs 2,654.1 million (USD 30.0 million) without admission of liability or wrongdoing. ESOP Allotment: During Q1FY27, the company allotted 53,425 equity shares of Rs 2/- each under ESOP plans, resulting in an increase of paid-up equity share capital by Rs 0.1 million. Nilesh Gupta, Managing Director, Lupin, said: “We are pleased to begin FY27 with a strong performance, driven by robust growth across our key markets and continued improvement in profitability. Our focus on execution, operational excellence, and sustained investments in technology and innovation continue to strengthen the business and position us for sustainable, profitable growth over the long term”. Result PDF